Predictive value of PSA halving index (PSAHI) in patients (pts) with hormone refractory prostate cancer (HPRC): Results from a randomized phase II trial with docetaxel (D) {+/-} estramustine phopshate (E)

Teodoro Sava,Evi Comploj,G. Fariello,Fable Zustovich,Romana Segati,C. Sacco,Alessandra Perin,M. Mandara,G. L. Cetto,Orazio Caffo

Predictive value of PSA halving index (PSAHI) in patients (pts) with hormone refractory prostate cancer (HPRC): Results from a randomized phase II trial with docetaxel (D) {+/-} estramustine phopshate (E)

2007

Teodoro Sava
Evi Comploj
G. Fariello
Fable Zustovich
Romana Segati
C. Sacco
Alessandra Perin
M. Mandara
G. L. Cetto
Orazio Caffo

15548 Background: D-based chemotherapy represents the standard treatment for HRPC pts. For several years PSA has been considered as a surrogate endpoint for studies involving pts with HRPC. The pos...

Keywords:

Estramustine
Oncology
Hormone refractory prostate cancer
Docetaxel
Medicine
Internal medicine
predictive value
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations